Hundreds of Skin Cancer Patients Trial mRNA Vaccine
Research moves into a major phase to determine the effectiveness and safety of mRNA vaccines in treating individuals battling melanoma.
The testing of an mRNA vaccine, believed by researchers to be potentially effective against melanoma, a type of skin cancer, has entered its third phase of clinical trials. According to a report by The Guardian, the trial, initiated and overseen by the University College London Hospitals NHS Foundation Trust, involves hundreds of skin cancer patients, each receiving a personalized vaccine.
Earlier, in the second phase of clinical trials, it was demonstrated that the mRNA vaccine developed against melanoma significantly reduced the likelihood of tumor recurrence. The expectation now is that the vaccine, which contains the messenger genetic material ribonucleic acid (mRNA), will "train" the body to "hunt down" cancer cells, thereby preventing the disease from returning.
Heather Shaw, the national coordinator of the study, stated that there is potential in vaccines to cure melanoma. However, mRNA-based vaccines are also being tested for other types of cancer, including lung, bladder, and kidney cancers.
The vaccine is, in essence, a personalized neoantigen therapy designed to stimulate the immune system when it needs to combat certain types of tumors. Known also as mRNA-4157 (V940), the vaccine targets tumor neoantigens, which are proteins that have undergone genetic mutations in cancer cells. These neoantigens serve as markers on the tumor that the immune system can recognize with the help of the vaccine preparation.
The vaccine carries the encoding for 34 neoantigens and activates an anti-tumor immune response based on the unique mutations of the patient's tumor. To personalize the vaccine, a sample is taken from the tumor during surgery, and DNA sequencing is performed with the aid of artificial intelligence. Consequently, each dose of the vaccine is uniquely effective for the individual patient.
In 2023, biochemist Katalin Karikó and microbiologist Drew Weissman were awarded the Nobel Prize in Physiology or Medicine for their development of the mRNA vaccine. The novel vaccines have significantly contributed to the mitigation of the coronavirus pandemic with their efficacy. For years, experiments have been ongoing to explore the use of the technology patented by Karikó and Weissman in 2005 against various types of cancer.
Earlier, in the second phase of clinical trials, it was demonstrated that the mRNA vaccine developed against melanoma significantly reduced the likelihood of tumor recurrence. The expectation now is that the vaccine, which contains the messenger genetic material ribonucleic acid (mRNA), will "train" the body to "hunt down" cancer cells, thereby preventing the disease from returning.
Heather Shaw, the national coordinator of the study, stated that there is potential in vaccines to cure melanoma. However, mRNA-based vaccines are also being tested for other types of cancer, including lung, bladder, and kidney cancers.
The vaccine is, in essence, a personalized neoantigen therapy designed to stimulate the immune system when it needs to combat certain types of tumors. Known also as mRNA-4157 (V940), the vaccine targets tumor neoantigens, which are proteins that have undergone genetic mutations in cancer cells. These neoantigens serve as markers on the tumor that the immune system can recognize with the help of the vaccine preparation.
The vaccine carries the encoding for 34 neoantigens and activates an anti-tumor immune response based on the unique mutations of the patient's tumor. To personalize the vaccine, a sample is taken from the tumor during surgery, and DNA sequencing is performed with the aid of artificial intelligence. Consequently, each dose of the vaccine is uniquely effective for the individual patient.
In 2023, biochemist Katalin Karikó and microbiologist Drew Weissman were awarded the Nobel Prize in Physiology or Medicine for their development of the mRNA vaccine. The novel vaccines have significantly contributed to the mitigation of the coronavirus pandemic with their efficacy. For years, experiments have been ongoing to explore the use of the technology patented by Karikó and Weissman in 2005 against various types of cancer.
Translation:
Translated by AI
